Forest hopes for 2011 approval of Daxas
This article was originally published in Scrip
Executive Summary
Forest Laboratories says it has addressed concerns raised in a US FDA complete response letter about lung drug Daxas (roflumilast). Forest says the FDA has acknowledged receipt of the resubmission, and the company expects a response from the agency in the first quarter of 2011.